Abstract
Criticism of HL ruling that patent for hepatitis B virus antigen was invalid because claim was too broad, insufficiently inventive and unsupported by disclosure.
| Original language | English |
|---|---|
| Pages (from-to) | 301-310 |
| Number of pages | 10 |
| Journal | International Journal of Biosciences and the Law |
| Volume | 1 |
| Issue number | 3 |
| Publication status | Published - 1 Jan 1997 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Threading an Antigen Through the Eye of Patentability to Sew Up Profits: Biogen Inc v Medeva plc'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver